Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for blood-derived products used in chronic non-healing wounds, effective May 15, 2026. Here's what billing teams need to do.
CMS blood-derived wound care coverage has been an active target for policy revision over the past several years. This update affects wound care practices, podiatrists, general surgeons, and outpatient wound centers billing for products like platelet-rich plasma and amniotic tissue-derived biologics. The policy document does not list specific CPT or HCPCS codes—we'll note that clearly below—so your billing team needs to map your current charge capture to the updated medical necessity criteria directly.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS |
| Policy | Blood-Derived Products for Chronic Non-Healing Wounds |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | High |
| Specialties Affected | Wound care, podiatry, general surgery, vascular surgery, plastic surgery, outpatient hospital wound centers |
| Key Action | Audit all active chronic wound cases billed under blood-derived product codes and confirm they meet updated medical necessity documentation standards before May 15, 2026 |
CMS Blood-Derived Products Coverage Criteria and Medical Necessity Requirements 2026
The CMS blood-derived products coverage policy governs when Medicare will pay for biological wound care treatments applied to chronic non-healing wounds. These products include platelet-rich plasma (PRP) preparations, platelet-derived growth factor therapies, and amniotic membrane or umbilical cord-derived products used to stimulate wound healing.
The core of any CMS coverage policy in this space is medical necessity. To support a covered claim, the wound must be chronic—meaning it has failed to progress through normal healing stages despite documented standard-of-care treatment. That standard of care typically includes adequate offloading for diabetic foot ulcers, compression therapy for venous leg ulcers, and sharp debridement, moisture management, and infection control across wound types.
Medical necessity documentation must show the wound type, the duration of treatment with conventional therapy, and the specific reason standard therapy failed. Without that documentation in the chart before the date of service, you're billing a claim that CMS can recoup on audit. That's not a theoretical risk—this is one of the highest-audit categories in outpatient wound care.
Prior authorization is not universally required under Medicare fee-for-service for these products, but Medicare Advantage plans administered through CMS-contracted payers frequently do require prior authorization. If your patients are Medicare Advantage, check each plan's requirements separately. Don't assume the fee-for-service rules apply.
The reimbursement structure for blood-derived products is complex because product cost, application, and any associated debridement are billed through separate codes. A policy modification that tightens coverage criteria tightens reimbursement across all of those line items simultaneously. That's why this change carries high impact.
CMS Blood-Derived Products Exclusions and Non-Covered Indications
CMS has consistently held that blood-derived products are not covered when used as a first-line treatment. This policy modification does not change that position—it reinforces it.
Products applied before a wound qualifies as "chronic" under Medicare's definition are not covered. A wound that has been present for less than four weeks, or one that has not received adequate conventional therapy, does not meet the bar. Billing for blood-derived products on a wound that lacks documented standard-of-care failure is the most common reason these claims get denied on medical review.
CMS also does not cover these products for acute surgical wounds, donor site wounds, or cosmetic applications. If your practice sees any of these wound types alongside chronic wound patients, your charge capture workflow needs a hard stop to confirm wound classification before a blood-derived product claim goes out.
Autologous PRP prepared outside of an FDA-cleared device, or products that lack sufficient clinical evidence to meet CMS's coverage standards, fall into the non-covered or experimental category. The line between "covered biological product" and "investigational biological product" is one of the most litigated in wound care billing. If you're unsure where a specific product lands, your compliance officer needs to review it before you bill—not after a denial.
Coverage Indications at a Glance
The policy document provided to PayerPolicy does not include indication-level criteria in a format that allows for a complete code-by-code breakdown. The table below reflects the general coverage framework CMS applies to this category, based on the structure of this coverage policy. Treat this as a starting framework—not a substitute for reading the full policy text at the source.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Chronic diabetic foot ulcer — failed standard care (≥4 weeks) | Covered when criteria met | Not listed in policy data | Must document offloading compliance and standard care failure |
| Chronic venous leg ulcer — failed standard care (≥4 weeks) | Covered when criteria met | Not listed in policy data | Must document compression therapy use and failure |
| Chronic pressure injury (Stage 3 or 4) — failed standard care | Covered when criteria met | Not listed in policy data | Must document repositioning, moisture management, debridement |
| Acute surgical wound | Not Covered | Not listed in policy data | Does not meet chronic wound definition |
| Wound with fewer than 4 weeks of conventional therapy | Not Covered | Not listed in policy data | Standard care failure not established |
| Investigational or non-FDA-cleared PRP preparation | Not Covered / Experimental | Not listed in policy data | Insufficient evidence for Medicare coverage |
| Cosmetic or aesthetic wound applications | Not Covered | Not listed in policy data | Outside the scope of covered wound care |
CMS Blood-Derived Products Billing Guidelines and Action Items 2026
The effective date of May 15, 2026 is your hard deadline. Here's what to do before and after it hits.
| # | Action Item |
|---|---|
| 1 | Audit your active wound care cases before May 15, 2026. Pull every patient with an open episode of care for a chronic wound who has received or is scheduled to receive a blood-derived product. Confirm each chart has documented proof of standard-of-care treatment, wound duration, and clinical rationale for escalating to a biological product. |
| 2 | Update your documentation templates now. Your intake and progress note templates should capture wound chronicity, prior treatment modalities, and treatment response (or lack thereof) in a structured, auditable format. A freetext narrative buried in a visit note won't hold up in a post-payment audit. |
| 3 | Separate product cost from application in your charge capture. Blood-derived wound care billing requires distinct line items for the product itself, the application procedure, and any debridement performed at the same encounter. Bundling these incorrectly is a fast path to a claim denial or a recoupment demand. |
| 4 | Verify prior authorization requirements for every Medicare Advantage patient. CMS fee-for-service rules do not bind Medicare Advantage plans on prior authorization. Before the first date of service, confirm each plan's requirements. Do this for every new episode of care, not just new patients. |
| 5 | Flag any blood-derived products you use that rely on LCD coverage rather than national coverage. Medicare Administrative Contractors publish local coverage determinations for some wound care biologics. If your MAC has a relevant LCD, this CMS policy change may interact with it. Check your MAC's website for updated LCDs with effective dates near May 15, 2026. |
| 6 | Brief your wound care providers directly. The documentation burden for these claims sits with the clinician, not the biller. Your providers need to understand that medical necessity for blood-derived products must be established in the chart before the claim is submitted—not reconstructed after a denial. Schedule that conversation before the effective date. |
| 7 | Talk to your compliance officer if you have high volume in this category. If blood-derived products represent meaningful revenue for your practice or wound center, the risk exposure here is proportional. A compliance officer or billing consultant who specializes in wound care can review your workflows against the updated coverage policy before May 15, 2026—not after your first post-payment audit. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Blood-Derived Products Under This Policy
The policy data provided to PayerPolicy for this update does not include specific CPT codes, HCPCS codes, or ICD-10-CM codes. We do not invent codes. Publishing fabricated codes would create real billing errors for your team.
That said, blood-derived wound care billing typically involves a known set of HCPCS and CPT codes for PRP preparation, biological product application, and wound debridement. The Centers for Medicare & Medicaid Services publishes the authoritative code list in the policy itself or in associated LCDs.
What to Do Instead
Access the full policy directly at the CMS source: https://app.payerpolicy.org/p/cms/217-v6
Cross-reference with your MAC's current LCDs for wound care biologics. Your MAC may have published code-level guidance that aligns with or supplements this national-level policy change.
If your practice management system uses charge capture rules tied to specific HCPCS codes for blood-derived products, pull that list and verify each code against the updated coverage criteria before May 15, 2026.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.